Skip to content
OpenCapital
Get started
Bristol-Myers Squibb logo

Bristol-Myers Squibb (BMY) Q1 2024 Earnings

BMY·Reported April 25, 2024·Before market open

Bristol-Myers Squibb reported Q1 2024 revenue of $11.9B, beat analyst consensus of $11.5B by $383.4M. Diluted EPS came in at $-4.40, beat the $-4.41 consensus by $0.01. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.

Revenue
$11.9Bbeat by $383.4M
Consensus: $11.5B
Diluted EPS
$-4.40beat by $0.01
Consensus: $-4.41
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000014272-24-000096

Financial Snapshot

Trailing eight quarters through Q1 2024

View all metrics

Q1 2024 Earnings FAQ

Common questions about Bristol-Myers Squibb's Q1 2024 earnings report.

Bristol-Myers Squibb (BMY) reported Q1 2024 earnings on April 25, 2024 before market open.

Bristol-Myers Squibb reported revenue of $11.9B and diluted EPS of $-4.40 for Q1 2024.

Revenue beat the consensus estimate of $11.5B by $383.4M. EPS beat the consensus estimate of $-4.41 by $0.01.

You can read the 10-Q periodic report (0000014272-24-000096) directly on SEC EDGAR. The filing index links above go to sec.gov.